Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma Inc. (COCP) provides this comprehensive news resource for tracking developments in its antiviral therapeutics pipeline. Access official press releases and verified updates on clinical trials, regulatory milestones, and strategic partnerships.
This page serves investors and industry observers seeking timely information about COCP's structure-based drug discovery platform and pipeline progress. Find updates on hepatitis C inhibitors, broad-spectrum influenza treatments, and norovirus antiviral candidates currently in development.
Content includes FDA correspondence, intellectual property filings, preclinical study results, and collaboration announcements with pharmaceutical partners. All materials are sourced directly from company disclosures to ensure regulatory compliance and factual accuracy.
Bookmark this page for consolidated access to Cocrystal Pharma's latest scientific advancements and business developments. Check regularly for updates on their mission to address unmet needs in viral disease treatment through innovative small-molecule therapeutics.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced a 1-for-12 reverse stock split approved by its Board of Directors, effective October 11, 2022. This move aims to maintain compliance with Nasdaq Rule 5550(a)(2), which requires share prices to be above $1.00 for 30 consecutive trading days to avoid delisting. Following the split, the outstanding shares will decrease from approximately 97.5 million to around 8.1 million, while the authorized shares remain at 150 million. No fractional shares will be issued, and existing equity awards will be proportionately adjusted.
Cocrystal Pharma, Inc. (Nasdaq: COCP) will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, via a hybrid model. James Martin, CFO and interim co-CEO, will present on-demand starting September 12 at 7:00 a.m. ET. Attendees can engage in virtual one-on-one meetings throughout the conference. Interested investors and industry professionals can register for attendance.
Cocrystal Pharma (Nasdaq: COCP) reported its Q2 2022 financial results and updates on antiviral pipeline developments. The company is advancing its oral PB2 inhibitor CC-42344, with a Phase 2a study planned to evaluate its efficacy against influenza A. Recent pharmacokinetic data supports once-daily dosing for CC-42344. Collaboration with NIAID is ongoing for COVID-19 protease inhibitors, with plans for two Phase 1 studies this year. Financially, Cocrystal faced a net loss of $24.4 million in Q2, including a $19.1 million non-cash goodwill impairment due to stock price decreases.
Cocrystal Pharma (Nasdaq: COCP) has completed the single ascending dose portion of its Phase 1 study for the antiviral candidate CC-42344, showing favorable pharmacokinetic data that supports once-daily dosing potential. The study, conducted in Australia, aims to assess safety and tolerability in healthy adults. Preliminary data indicated a positive safety profile for doses of 100 mg and 200 mg. CC-42344 acts as a PB2 inhibitor and demonstrates antiviral activity against resistant influenza A strains, potentially outperforming existing treatments like Tamiflu.
Cocrystal Pharma, Inc. (Nasdaq: COCP) has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical studies on its 3CL protease inhibitors for COVID-19 treatment. This collaboration will support the scale-up synthesis of a key intermediate necessary for the development of these inhibitors. Cocrystal aims to create antiviral drugs targeting viral replication proteins, potentially beneficial against various coronaviruses, including COVID-19.
Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced that James Martin, Chief Financial Officer and co-interim CEO, will present a company overview at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 10:00 a.m. Eastern Time. This hybrid event will take place at the Fontainebleau Miami Beach Hotel. A live webcast of the presentation will be available on the company’s IR Calendar and archived for 90 days.
Cocrystal specializes in developing antiviral therapeutics targeting influenza, coronaviruses, and more.
Cocrystal Pharma, Inc. (Nasdaq: COCP) reported a net loss of $4.2 million for Q1 2022, consistent with the previous year. The company is advancing its antiviral programs, announcing positive preliminary data from its Phase 1 study of CC-42344 for influenza A. Cocrystal is also collaborating with NIAID to evaluate COVID-19 protease inhibitors and preparing for a Phase 1 study of inhalation and oral inhibitors for COVID-19 treatment.
As of March 31, 2022, Cocrystal had $54.8 million in cash, sufficient to fund operations through 2023.
Cocrystal Pharma (Nasdaq: COCP) has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to conduct exploratory preclinical studies on its SARS-CoV-2 3CL protease inhibitors for potential COVID-19 treatment. Cocrystal's novel inhibitors demonstrate potent in vitro efficacy against SARS-CoV-2 and variants, including Omicron. This collaboration aims to further evaluate the antiviral activity of these compounds in both in vitro and in vivo settings.
Cocrystal Pharma (Nasdaq: COCP) will present at the Life Science Innovation Northwest 2022 conference on April 20-21, 2022, at the Washington State Convention Center in Seattle. Sam Lee, PhD, President and co-interim CEO, is set to deliver a presentation during the Neuroscience & Pharmaceuticals segment on April 20 at 3:25 PM Pacific. This conference is the Pacific Northwest’s largest annual life science event, aiming to connect investors, researchers, and organizations to discuss significant life science breakthroughs.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that James Martin, Chief Financial Officer and co-interim CEO, will present at the NobleCon18 Investor Conference on April 21, 2022, at 9:30 a.m. ET, held at the Hard Rock Hotel & Casino in Hollywood, Florida. A video webcast of the presentation will be available the next day on the Company's website, as well as on Noble Capital Markets’ and Channelchek's websites, archived for 90 days.
Cocrystal, a clinical-stage biotechnology company, focuses on developing novel antiviral therapeutics targeting various viruses.
